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1.          INTRODUCTION 
 
 
1.1 HCN channels. General overview. 
 
The hyperpolarization-activated cyclic nucleotide-gated (HCN) channel family implies four 
members (HCN1-4) which are expressed in the heart and the nervous system. The current 
flowing through HCN channels was termed as If or Ih or Iq. It was demonstrated that the 
heterogeneity of native Ih currents is attributable to, at least partly, the tissue-specific 
expression of HCN channel genes [1]. The hyperpolarization–activated current was named 
"funny" current (If) in the heart because of its unusual electrophysiological characteristics [2], 
while this current in the nervous system was designated Ih (for "hyperpolarization") or Iq (for 
"queer" current). If/Ih current plays a substantial role in the initiation and control of the heart 
rate [3]. If/Ih generates rhythmic activities particularly in thalamocortical circuits, has a 
function in regulating synaptic integration (e.g. in prefrontal pyramidal neurons) [4], in 
neuronal cells takes part in the determination of resting membrane potential [5] (Ih is inward, 
and the others (Kir2 and Kleak) are outward, there is dynamic equilibrium between them), 
probably plays an important role in olfactory information processing [6], generates and 
controls oscillations of the membrane potential. The increased expression level of Ih and HCN 
isoforms in sensory nerves indicates that they might play a prominent role in sensory function 
[7] (e.g. by modulating pain thresholds) and could be targets in analgesic therapy in special 
conditions e.g. nerve injury based neuropathic pain. Interestingly, it turned out that some 
volatile anaethetic agents are able to influence the operation of HCN channels, opening an 
other significant field in drug research. HCN isoforms have also been found in pancreatic 
beta-cells and kidney, where they regulate important physiological functions [8-10]. HCN 
channels are expressed in the retina [11]. Ivabradine is a novel heart rate-lowering antianginal 
agent which inhibits the pacemaker current in the heart with high selectivity. According to the 
BEAUTIFUL study, ivabradine can be used to reduce the incidence of coronary artery disease 
outcomes in a subgroup of patients who have heart rates of 70 bpm or greater [12]. A large 
proportion of patients suffering from heart failure die of sudden cardiac death caused by 
arrhythmia. It emerged from experiments analyzing the expression pattern of HCN channel 
isoforms in failing heart that suppressing the activity of the upregulated HCN channel 
subtypes can probably preclude the development of that type of arrhythmias which are 
triggered by abnormal pacemaker activity in the working myocardium, as it was found that 
both mRNA and protein levels of HCN2 and HCN4 isoforms were significantly augmented in 
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failing ventricles [13]. Therefore, selective HCN blockers might serve as effective agents of 
this profile. HCN4 is the predominant isoform in undiseased human heart, and its expression 
is increased by disease (e.g. heart failure). The classic antiarrhythmic compounds might exert 
little or insignificant effect on this isoform as recently it turned out that the blocking effects of 
them /quinidine, disopyramide, cibenzoline, lidocaine, mexiletine, aprindine, propafenone, 
flecainide, propranolol, and verapamil/ on the HCN4 channel current were weak, D,L-sotalol 
hardly influenced the HCN4 channel current in clinical concentrations in HEK293 cells [14].  
 
1.2 HCN channels in the heart 
 
Heart rate is regulated by spontaneous electrical pacemaker activity in the sino-atrial node 
mainly controlled by the If current. The If current determines the slope of diastolic 
depolarization and cardiac frequency, and its inhibition causes heart rate reduction. The 
´funny´ (If)  current is so termed because of its unusual characteristics, including that of being 
an inward current that is activated on hyperpolarization and not on depolarization like other 
known currents [15]. The role of currents other than If and cellular mechanisms (ICaL, ICaT, INa, 
IKr, Ist, INCX, intracellular Ca2+ cycling = "calcium clock") in pacemaker activity is also 
important and it is still argued [16]. Nevertheless, it can be stated that If plays a principal role 
in regulating sinoatrial node pacemaker activity [3]. It is generally agreed that it has 
modulatory effect on pacemaker rate. HCN channels (hyperpolarization-activated cyclic 
nucleotid-gated) are responsible for generating the If pacemaker current in the heart. The 
channel relating to the cardiac If current is known to be a member of a family of channels 
denominated the hyperpolarization-activated cyclic nucleotid-gated (HCN) channels. The If 
current is controlled by opposite processes, i.e. the beta adrenergic stimulatory and muscarinic 
cholinergic inhibitory actions occur via adenylate cyclase and cAMP [17]. The If is a mixed 
Na+ and K+ current that is activated on hyperpolarization to voltages within the pacemaker 
range. Recently, Ca2+ influx through HCN channels has indirectly been postulated and then 
directly the Ca2+ permeability of native rat and human If has been shown [18].  
Heart rate has a prominent role in the development and pathophysiology of myocardial 
ischaemia. In patients with coronary artery disease, ischaemic episodes could be generated by 
an elevation in heart rate that elicits imbalance between myocardial oxygen supply and 
demand. Therefore, lowering the heart rate is regarded as an important therapeutic target in 
preventing ischaemia by reducing myocardial oxygen consumption. Therefore, reducing heart 
rate is one of the most important therapeutic possibilities in the treatment of stable angina 
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pectoris [19, 20]. Additionally, resting heart rate is associated with the severity and rate of 
progression of coronary atherosclerosis and is an independent predictor of plaque rupture in 
coronary arteries, therefore, heart rate lowering e.g. by ivabradine the specific HCN blocker 
should prevent atherosclerosis and cardiovascular events [21]. 
The current pharmacological treatment of stable angina pectoris is based on beta adrenoceptor 
blockers, calcium channel antagonists, nitrates and trimetazidine with beneficial metabolic 
effect on the heart. The antiischemic effect of beta blockers is attributable, at least in part, to 
heart rate reduction. Beta blockers apart from the numerous, proven, valuable effects in the 
treatment of cardiovascular diseases (angina pectoris, myocardial infarction, heart failure, 
arrhythmias) have several side effects including fatigue, depression, change in lipid status, 
sexual dysfunction, bronchospasm, atrioventricular block, possible increase in blood sugar 
level, rebound phenomena. They can cause paradoxical vasoconstriction of large epicardial 
arteries [22] during exercise or in patients with resting angina associated to coronary 
vasospams. Beta blockers (except carvedilol and nebivolol) may be contraindicated in patients 
with peripheral vascular disease. Concerning the nitrates headache, regarding the calcium 
channel blockers pedal edema are potential side effects. The hemodynamic effects might be 
also limiting factors at application e.g. the negative inotropic effect of the beta blockers, the 
considerable blood pressure lowering property of the calcium channel blockers. In ST-
segment elevation myocardial infarction (STEMI) early i.v. use of beta blockers is clearly 
contraindicated in patients with clinical signs of hypotension or congestive heart failure [23]. 
Therefore, highly selective HCN channel blockers, producing solely heart rate lowering, e.g. 
ivabradine, lacking the negative inotropic effect, may offer a new therapeutic perspective in 
the treatment of ischaemic heart diseases e.g. in stable angina pectoris, particularly in patients 
with left ventricular dysfunction. Based on the recent clinical trials and experiments, widening 
the indication of ivabradine for the treatment of heart failure or myocardial infarction is 
expected. Thus, to seek for specific blockers of the If current is in the focus of cardiovascular 
pharmacological research.  
 
1.3 Characteristics of the If current and its role in the adrenergic and cholinergic 
modulation of heart rate   
 
The sino-atrial node (SAN) is a small, specialized structure located in the right atrium. The 
nodal cells (specialized myocytes) generate pacemaker activity, i.e. their diastolic membrane 
potential is unstable, a gradual depolarization to a threshold occurs. If current is deactivated 
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during the upstroke of an action potential. Upon repolarization when membrane potential 
reaches the If activation voltage (below -40 mV), If becomes activated, and its slow activation 
counteracts the repolarizing IK and slowly depolarizes the membrane voltage [24]. Reaching 
the threshold a new action potential is elicited. The potential ionic currents and mechanism 
responsible for the pacemaker activity are as follows: If, ICaL, ICaT, INa, IKr, Ist, INCX and probably 
the pacemaker function is dependent on complex interactions between localized, 
subsarcolemmal Ca2+ releases and action potentials [25]. The role of If  in the control of the 
firing rate of the sino-atrial node and therefore determining the heart rate is heavily argued  
[3,16,26]. The clinical studies might give proof of the considerable influence of If on the 
pacemaker function, as the highly specific If current blocker ivabradine used in the trials 
reduced heart rate by 10 to 15 beats/min [27].  
The heart, regarding its control by the autonomic nervous system, receives both sympathetic 
(responsible for increasing the heart rate, via stimulation of β1 adrenoceptors) and 
parasympathetic (liable for decreasing the heart frequency, through activation of M2 
cholinergic receptors) innervation. The predominant tone is the parasympathetic, mediated by 
acetylcholine. At least in rabbits, functional inhomogeneity of the sinus node is possibly 
responsible for the predominance of the effect of acetylcholine over that of adrenaline [28]. 
Cyclic AMP is a second messenger in the acetylcholine inhibitory action on the If  pacemaker 
current, the parasympathetic cholinergic-stimulated decrease of intracellular cyclic AMP 
concentration occurs via inhibition of a high basal adenylate cyclase activity [29]. 
Sympathetic stimulation by noradrenaline (via increasing the activity of adenylate-cyclase 
resulting in a higher intracellular cAMP level) increases the If  current during 
hyperpolarizations [30] and accelerates its activation rate. The second messenger cAMP 
promotes HCN (If) channel opening by direct binding to the C-terminal channel domain. 
Therefore, compounds that increase If current (e.g. beta1 adrenoceptor agonists) accelerate 
heart rate and conversely, substances that decrease If current (e.g. acetylcholine) slow heart 
rate. 
In 1979, the If pacemaker current was first described in the sino-atrial node cells by Brown, 
DiFrancesco and Noble in Oxford [2]. According to its special property, i.e. being activated 
on hyperpolarization, this inward current was nominated as the "funny" current. Later,  If  was 
identified in atrial and ventricular myocytes [31,32]. A similar current, denominated Ih, was 
identified in several different types of neurons (responsible for controlling excitability, 
integrating synaptic activity) and in retina cells [33]. The If  pacemaker current is an inward 
current activated by both voltage hyperpolarization and increase in intracellular cAMP. Cyclic 
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AMP activates If current by a mechanism other than  phosphorylation, implying a direct 
interaction with the channels at their cytoplasmic side [34]. Cyclic AMP stimulates If by 
shifting its activation curve to more positive voltages [34]. According to an allosteric model 
cAMP has a higher binding affinity to open than to closed channels [35]. If is enhanced by 
beta1 adrenoceptor activation, and is decreased by acetylcholine. If current possesses slow 
kinetics of activation and deactivation (i.e. most If/Ih channels activate quite slowly with time 
constants ranging between hundreds of milliseconds and seconds [11]). If  is carried by a 
mixture of Na+ (the major contributor) and K+ ions [36]. Recently, Ca2+ entry through HCN 
channels has indirectly been postulated and then directly the Ca2+ permeability of native rat 
and, more importantly human If in the presence of physiological extracellular Ca2+ 
concentrations at the physiological resting membrane potential has been shown [18]. 
Representative values of mid-activation voltages of If current [37] measured in the sino-atrial 
node cells are in the range of -60 to -70 mV. In human sino-atrial cells activation threshold 
has been reported to be between -50 and -60 mV [38]. If  kinetics and activation range are 
modulated by cAMP (see above); auxiliary subunits e.g. MinK-related protein (MiRP1) co-
assembling with HCN2/ acting as a β subunit for HCN2 pacemaker channel subunits resulting 
in larger If current with more rapid activation and deactivation kinetics [39]. Other processes 
contributing to adjustment of the current activation range and kinetics are phosphorylation-
dependent mechanisms (possible candidates for the phosphorylation events are protein kinase 
A, C, tyrosine kinases) as phosphorylation increases If conductance, potentiates the action of 
isoproterenol on If [40]; interaction with structural proteins e.g. binding to filamin A slows 
HCN1 channel kinetics and reduces the density of channel expression and whole-cell 
conductance [41]. Recently, evidence for a major role of other regulatory elements of HCN 
current has been indicated. Among these are phosphatidylinositol 4,5 bisphosphate 
(PI(4,5)P2), and caveolin 3. PI(4,5)P2, can induce positive shifts in voltage dependence [42]. 
Disorganization of caveolin-rich microdomains in the membrane is able to shift the activation 
curve of HCN channels toward more positive voltages [43]. HCN channels are also regulated 
by intracellular pH, intracellular increase in protons shifts the voltage dependence of 
activation to more negative potentials leading to inhibition of channel operation.   
  
1.4 If current inhibitor heart rate-reducing agents  
 
In accordance with the prominent role of If current [3,44] in the generation and autonomic 
control of spontaneous activity in the sino-atrial node, selective inhibition of the pacemaker 
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current is expected to be able to modify the slope of diastolic depolarization, therefore to 
modulate cardiac chronotropy without influencing other cardiovascular parameters e.g. 
inotropy, impulse conduction or repolarization. 
At the end of 1980s, relatively selective inhibitors of the If current, e.g. the first described 
alinidine and falipamil, were termed as "specific bradycardic agents, SBAs" [45]. Later, 
compounds acting by the same mechanism have been denominated as "heart rate-lowering" 
agents. They perform cardiac slowing without the negative inotropic side effect and ideally 
without slowing down atrioventricular (AV) conduction, characteristic for the classic, 
currently used drugs (beta receptor blockers and Ca2+ antagonists) also aiming to reduce heart 
rate.  
Specific bradycardic agents can be grouped into three different chemical classes: 
phenylalkylamines such as zatebradine, imidazolines such as alinidine, and ZD7288, which is 
the only diaminopyrimidine whose activity on HCN channel has been reported. 
Alinidine was the first bradycardic agent with known sino-atrial pacemaker current (If) 
inhibitory property which is an imidazoline compound derived from clonidine. Further 
bradycardic substances (also termed as newer "sinus node inhibitors" SNIs) have been derived 
from the calcium channel inhibitor verapamil, e.g.: falipamil, cilobradine, zatebradine and 
ivabradine. 
Alinidine (ST567), (N-allyl-clonidine), reduced the spontaneous frequency and the slope of 
diastolic depolarization dose-dependently and prolonged repolarization in rabbit [46] and 
guinea pig [47] sino-atrial node cells. Due to the voltage clamp experiments, the underlying 
ionic currents responsible for these changes in configuration of the action potentials turned 
out to be –concerning the repolarization lengthening- the reduced outward current (Ik) and –
regarding the frequency and slope- the decreased hyperpolarization-activated inward current 
(If) [46]. Regarding If current block no use or frequency dependence were reported indicating 
that alinidine binds equally to open and closed channel states. Lack of specificity e.g. the 
ability of alinidine to block of K+ channels in similar concentrations exerting bradycardic 
effect and the consequent action potential prolongation and negative inotropism [47] and 
visual side-effects [48] resulted that its development was discontinued.  
The verapamil analogue falipamil (AQ-A39), (2-(3-{[2-(3,4-dimethoxyphenyl)ethyl]methyl-
amino}propyl)-5,6-dimethoxy-2,3-dihydroisoindol-1-one hydrochloride) apart from reducing 
sino-atrial frequency by blocking If [49], possesses several unwanted receptorial actions e.g. it 
exhibits direct vagolytic effect, via a competitive action of the drug with acetylcholine at the 
muscarinic receptor [49, 50], reduces (the time-dependent) potassium current (IK), blocks 
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calcium channels [49]. Similarly to zatebradine (below), the block of If conductance presents 
use-dependence with falipamil. The proarrhythmic effects attributable to excessive potassium 
and calcium channel blockade resulted in discontinuing the development of this drug. 
The benzazepinone derivative zatebradine (UL-FS49; /1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-
[[2-(3,4-dimethoxy- phenyl)ethyl ]methylimino]propyl]-2H -3-benzazepin-2-one 
hydrochloride/), is a bradycardic compound that blocks the hyperpolarization-activated 
current (If) in the rabbit sinoatrial node. Zatebradine behaves as an open channel blocker of 
(If) channels, block occurs within the pore, at a distance of about 39% of the membrane 
thickness from its internal side [51]. Zatebradine-induced block is use dependent [52]. 
Zatebradine is able to block hKv1.5 [52], prolongs AP duration [53] in concentrations 
exerting bradycardic effect. Zatebradine exerted positive inotropic actions in guinea pig 
papillary muscles [47]. A phase III clinical trial ascertained that zatebradine seems to provide 
no additional antianginal benefit to patients already receiving nifedipine [54]. Moreover, 
patients taking zatebradine experienced visual disturbances. Patch-clamp recordings from 
newt rod photoreceptor cells showed that zatebradine caused use- and concentration-
dependent (0.1-100 µM) inhibition of  Ih , which may explain its effects on the 
electroretinogram (ERG) in vivo and its adverse effects on vision in clinical studies [55].  
Cilobradine (DK-AH269), a newer congener of zatebradine induced a more effective (2-fold 
higher) and faster block of If in sino-atrial node myocytes than zatebradine [56]. Similarly to 
falipamil and zatebradine, cilobradine produced a use-dependent block of If. Cilobradine 
requires open channels to access the binding site and acts intracellularly. Block by cilobradine 
is voltage-dependent and is relieved by strong hyperpolarization. Cilobradine performed 
considerable (~22%) IK reduction in mouse sino-atrial node cells at 5 µM, only preclinical 
studies were accomplished [57].  
Zeneca ZD 7288 (also known as ICI-D7288), which is a lipophilic quaternary cation, is a 
distant analogue of alinidine. The block of ZD7288 (4-(N-ethyl-N-phenylamino)-1,2-
dimethyl-6-(methylamino) pyrimidinium chloride) on If current is not use-dependent, whereas 
zatebradine (UL-FS 49) displays use-dependent If current inhibition. The lack of use-
dependence in the effect of ZD7288 on If current might reflect an affinity of the drug for the 
closed or resting state of the channel, resulting in the development of inhibition even in the 
absence of activation. Distinctly, zatebradine (UL-FS 49) performs small or no inhibition of 
the current in the absence of activation. ZD7288 had no significant effect on the delayed 
rectifier potassium current (IK) in guinea-pig dissociated sinoatrial node cells, but both 
alinidine and zatebradine (UL-FS 49) significantly inhibited IK at the same concentrations 
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which decreased If  [58]. Although ZD7288 is usually represented as pyridinium ion, it is 
likely that at physiological pH the non-ionic structure is present in sufficient amount to allow 
the penetration of the compound through the cell membrane [58]. In different regions of the 
central nervous system (rat hippocampal CA1 neurons, guinea pig substantia nigra neurons, 
thalamocortical neurons of the cat ventrobasal thalamus) ZD7288 considerably blocked the 
hyperpolarization-activated current (Ih) [59-61]. 
The compound YM758 (Fig.2), [(-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline-2-carbonyl)piperidin-1-yl]ethyl}-4-fluorobenzamide monophosphate], 
a novel If current blocker, was being developed as a treatment for stable angina and atrial 
fibrillation by Astellas Pharma and has recently been discontinued [62]. 
 
1.5 Heart rate reduction with a highly selective If inhibitor: ivabradine (S16257) 
 
The resolution of the benzocyclobutane derivative S 15544 (a racemate compound) into its 
two isomers S 16257 (S configuration) and S 16260 (R configuration) provided the compound 
S 16257, ivabradine, an optically pure molecule [63]. Both isomers reduced the spontaneous 
firing of rabbit sinus node preparations. S 16260 lengthened ventricular repolarization [64], 
which is a potential proarrhythmic effect. The electrophysiological selectivity of S 16257 
made it possible its further preclinical evaluation. The chemical formula of ivabradine is [3-
(3-{[((7S)-3,4-dimethoxybicyclo-[4,2,0]-octa-1,3,5-trien-7-yl)methyl]-methylamino}-propyl)-
1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one hydrochloride].  
Ivabradine is a novel antianginal agent, a potent blocker of the pacemaker current, which has 
significantly weaker ability to block other ion currents than its predecessors. Ivabradine 
(Procoralan®, Coralan®, Corlantor®) is an anti-ischaemic agent, which inhibits the If current 
with high selectivity [65, 66]. Ivabradine induces a marked exponential use-dependent 
blockade of the hyperpolarization activated If current. The IC50 for the block of If is 2.8 µM 
[65]. It has been shown that a high concentration of ivabradine (10 µM) has no detectable 
effect on T-type calcium current and slightly decreases L-type calcium current without 
significant use-dependent block. Also it moderately decreases the delayed outward potassium 
current in rabbit sino-atrial node cells [65]. The effect of ivabradine on the action potential 
repolarization was studied in guinea pig papillary muscle and rabbit sinus node pacemaker 
cells [53, 64]. In these preparations ivabradine did not show considerable effect on action 
potential duration at therapeutically relevant concentrations. Ivabradine blocks ion flow 
(through HCN channels) from the cytoplasmic side of the membrane through competing with 
 15 
permeating ions in their binding to specific ion binding sites in the single file permeation 
pathway of the HCN channels [67]. Ivabradine blocks HCN channels from the cytoplasmic 
side requiring drug molecules to enter the cell before acting ("open channel" block). Use 
dependence appears as a slowly progressing block accumulation during repetitive channel 
activation/deactivation cycles. The If inhibition by ivabradine is highly voltage-dependent, 
being stronger at depolarized voltages [67, 44], and current dependent, since the direction of 
current influences the stability of its binding in the pore of the channel. The study [68] 
investigated the blocking action of ivabradine on mouse (m) HCN1 and human (h) HCN4 
channels heterologously expressed in HEK293 cells revealed IC50s of 0.94 µM for mHCN1 
and 2.0 µM for hHCN4. 
 
1.6 Therapeutical advantages of ivabradine in coronary artery disease and heart failure 
patients  
 
Ivabradine is the only clinically available selective heart rate-reducing drug, and it exerts anti-
ischaemic effects in patients with chronic stable angina [69]. Ivabradine has been associated 
with a good safety profile during its clinical development [70]. In a trial, mild, tolerable visual 
symptoms (e.g. abrupt changes in light intensity) were reported as side effects [27]. Contrary 
to several heart rate-reducing drugs, ivabradine lowers heart rate both at rest and during 
exercise without producing any negative inotropic or vasoconstrictor effect. The bradycardic 
effect of ivabradine is proportional to the resting heart rate, the effect tends to plateau. 
Therefore, severe sinus bradycardia is not common. In a study [71] with healthy volunteers it 
has been demonstrated that for a similar decrease in heart rate at rest and during sympathetic 
stimulation, acute administration of ivabradine decreased myocardial oxygen demand to the 
same extent as a reference beta-blocker, propranolol, but withot proof of depressant action on 
cardiac function. The advantages of heart rate-lowering by beta-blockers are in part 
counterbalanced by unmasked alpha-adrenergic coronary vasoconstriction, therefore selective 
heart-reducing compounds might be able to decrease heart rate without unmasking alpha-
adrenergic coronary vasoconstriction [69].    
The INITIATIVE study compared the anti-anginal and anti-ischaemic effects of ivabradine 
and the beta receptor blocker atenolol and revealed that ivabradine is as effective as atenolol 
in patients with stable angina [72]. The ASSOCIATE study evaluated the anti-anginal and 
anti-ischaemic efficacy of ivabradine in patients with chronic stable angina pectoris receiving 
beta-blocker therapy and found that the combination of ivabradine 7.5 mg b.i.d. and atenolol 
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at the commonly used dosage in clinical practice in patients with chronic stable angina 
pectoris produced additional efficacy with no untoward effect on safety or tolerability [73]. 
According to the BEAUTIFUL trial, in patients with coronary artery disease and left-
ventricular systolic dysfunction ivabradine can be used to reduce the incidence of coronary 
artery disease outcomes (e.g. hospitalization for myocardial infarction and coronary 
revascularization) in a subgroup of patients who have heart rates of 70 bpm or greater [8]. The 
placebo arm of this trial which was a large cohort of patients with stable coronary artery 
disease and left-ventricular dysfunction showed that elevated heart rate was associated with 
an increased risk of adverse fatal and non-fatal cardiac events. The results of the recent 
SHIFT study (also) support the significance of heart-rate reduction with ivabradine for 
improvement of clinical outcomes in heart failure and confirm the important role of heart rate 
in the pathophysiology of this disorder [74].  
Moreover, an increased heart rate has been demonstrated to be associated with more 
pronounced atherosclerosis progression and a higher risk of coronary plaque rupture. Heart 
rate lowering has slowed atherosclerosis progression and improved endothelial function in 
experimental models [21]. 
 
1.7 Future possibilities: ivabradine as a reasonable alternative to beta receptor blockers in 
myocardial infarction, results with ivabradine in experimental models of myocardial 
infarction  
 
In acute myocardial infarction, the negative inotropic and hypotensive effects of beta receptor 
blockers contraindicate their use in patients with borderline blood pressure, pulmonary 
congestion, manifest pulmonary edema, or cardiogenic shock. After myocardial infarction, for 
chronic therapy beta receptor blockers are considered as a first-line therapy but side effects 
e.g. fatigue, change in lipid status, sexual dysfunction, bronchospasm, atrioventricular block 
may limit their use [75]. Ivabradine is devoid of negative inotropic effect and does not 
influence coronary vasomotion, and it has no impact on blood pressure and AV node 
conduction. These favourable properties might put ivabradine in a status to lower heart rate in 
unstable patients. Ivabradine improves myocardial stunning following myocardial ischaemia 
better than beta receptor blockade. In a recent study performed in a rabbit model of  
myocardial infarction, ivabradine improved  global and regional systolic function of the 
reperfused heart [76]. Previously, improvement of regional myocardial blood flow and 
function and reduction of infarct size by ivabradine have also been described [77]. Also, 
 17 
chronic treatment with ivabradine positively affected global cardiac remodelling in post-
myocardial infarcted rats [78]. 
 
1.8 HCN channels and arrhythmogenesis 
 
It has been shown that cardiac HCN4 isoforms are fundamental for physiological heart 
impulse generation and conduction in adult mice supporting that dysfunctional HCN4 
channels might be a direct cause of arrhythmias [79]. HCN4 is the main isoform (based on 
mRNA analysis) expressed in human sino-atrial node (hSAN) and ivabradine blocks this 
channel in a use-dependent way [80]. In rabbit atrioventricular node (AVN) and human 
Purkinje fibres HCN4 is the main isoform expressed [81, 82]. In human, the main HCN 
isoforms both in atria and ventricles are HCN4 and HCN2 [13, 57, 83]. HCN upregulation 
probably contributes to increased If and may play a role in ventricular and atrial 
arrhythmogenesis in heart failure. If overexpression has been reported in failing human hearts 
[84, 85]. In diseased human hearts, current density is higher in ischemic than in dilated 
cardiomyopathy, indicating that functional If overexpression is related to the etiology of the 
disease [86]. At the mRNA and protein level, it has been documented that HCN2 and HCN4 
isoforms are upregulated in failing human ventricles [13]. Single-channel, cell-attached 
recordings carried out in human atrial myocytes [87], showed that activation potentials were 
more positive than previously suggested in whole-cell measurements, supporting the idea that 
If might contribute to arrhythmogenesis in disease states described by If overexpression e.g. 
heart failure, cardiac hypertrophy (also HCN2 and HCN4 are upregulated) [44]. Altered 
expression of HCN channels as a result of electrophysiological remodeling may represent an 
arrhythmogenic mechanism in heart failure, therefore HCN4 or HCN2 specific or HCN4/2 
preferring If blockers might be considered as potential therapeutic agents which may modulate 
abnormal automaticity [13, 84, 85].  
 
1.9 Recently synthesized HCN channel blockers 
 
In order to design isoform-selective phenylalkylamines, Melchiorre et al. tested compound 
EC4, and its cis isomer EC32, on HEK cells stably expressing mHCN1, mHCN2 and hHCN4 
channel isoforms [88]. It was found that these molecules show different ability to block Ih 
current: in particular, while EC4 shows a preference for the HCN1 channel over HCN2 and 
HCN4, EC32 blocks the HCN2 channel more potently than HCN1 and HCN4. These findings 
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lead  to the discovery of analogs with improved selectivity, allowing to derive some 
preliminary structure-activity relationships. In particular: a R absolute configuration is 
important for a strong interaction with the HCN2 channel (MEL55A), and therefore to gain 
selectivity for one isoform over the others; the increase of steric bulkiness on the basic 
nitrogen seems to drive the activity only on the HCN1 subtype, as suggested by the high 
selectivity of compound MEL57A, R isomer. Moreover, the incorporation of spacer B into a 
cyclohexane ring gave compound EC18, which interacts selectively with the HCN4 isoform 
with respect to HCN1 and HCN2, [89] suggesting that cyclic constraints seem necessary to 
achieve selectivity for the HCN4 isoform.  
1.10 Aims of the study 
The main goal of the present study was to describe in detail the cellular cardiac 
electrophysiological effects of compounds ivabradine and EC18 and MEL57A in dog and 
human heart preparations using standard microelectrode technique. The effect of ivabradine 
on the action potential repolarization was only studied in guinea pig papillary muscle and 
rabbit sinus node pacemaker cells [53, 64], i.e. in species having relatively small hearts with 
high frequencies. In these preparations ivabradine did not show considerable effect on action 
potential duration at therapeutically relevant concentrations, and at high concentration (50 
µM) it produced frequency-dependent Vmax block in guinea-pig papillary muscle [90]. The 
effects of ivabradine on Vmax, repolarization and spontaneous depolarization have not yet been 
reported in human isolated cardiac preparations and in large animals close to human in heart 
size and spontaneous frequency. We investigated the important question whether these 
substances might possess subsidiary anti –and/or proarrhythmic actions. 
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2. MATERIALS AND METHODS 
2.1 Whole cell configuration of the patch-clamp technique 
 
Ventricular myocytes were enzymatically dissociated from hearts of mongrel dogs or rabbits 
of either sex weighing 10 – 15 kg and 1-2 kg, respectively, as described earlier in detail 
[91,92]. One drop of cell suspension was placed within a transparent recording chamber 
mounted on the stage of an inverted microscope, and individual myocytes were allowed to 
settle and adhere to the chamber bottom for at least 5 minutes before superfusion was 
initiated. Only rod shaped cells with clear cross striations were used. HEPES buffered 
Tyrode's solution served as the normal superfusate. This solution contained (in mM): NaCl 
144, NaH2PO4 0.33, KCl 4.0, CaCl2 1.8, MgCl2 0.53, Glucose 5.5, and HEPES 5.0 at pH of 
7.4. Patch-clamp micropipettes were fabricated from borosilicate glass capillaries using a P-
97 Flaming/Brown micropipette puller (Sutter Co, Novato, CA, USA). These electrodes had 
resistances between 1.5 and 2.5 MΩ when filled with pipette solution containing (in mM): 
KOH 100, KCl 40, K2ATP 5, MgCl2 5, EGTA 4, CaCl2 1.5 and HEPES 10. The pH of this 
solution was adjusted to 7.2 by aspartic acid. Measuring K+ currents, nisoldipine (1 µM) (gift 
from Bayer AG, Leverkusen, Germany) was added to the external solution to eliminate 
inward L-type Ca2+ current (ICa). The rapid delayed rectifier potassium current (IKr) was 
separated from slow IKs component by using the selective IKs blocker HMR-1556 (0.5 µM). 
Membrane currents were recorded with Axopatch-200B patch-clamp amplifiers (Molecular 
Devices –Axon Instruments, Union City, CA, USA) using the whole-cell configuration of the 
patch-clamp technique. After establishing a high (1-10 Gohm) resistance seal by gentle 
suction, the cell membrane beneath the tip of the electrode was disrupted by suction or by 
application of 1.5 V electrical pulses for 1 - 5 ms. The series resistance was typically 4 - 8 
MΩ before compensation (50 - 80%, depending on the voltage protocols). Experiments where 
the series resistance was high, or substantially increased during measurement, were discarded. 
Membrane currents were digitized using analog-to-digital converters (Digidata 1200 and 
Digidata 1322, Molecular Devices –Axon Instruments, Union City, CA, USA) after low-pass 
filtering at 1 kHz under software control (pClamp 8.0 Molecular Devices –Axon Instruments, 
Union City, CA, USA). The same software was used for off-line analysis. All patch-clamp 
data were collected at 37 °C.  
 
2.2 Conventional microelectrode technique 
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2.2.1 Dog tissue 
All experiments were carried out in compliance with the Guide for the Care and Use of 
Laboratory Animals (USA NIH publication No 85-23, revised 1985). The protocols were 
approved by the Review Board of the Committee on Animal Research of the University of 
Szeged (54/1999 OEj). Ventricular muscles were obtained from the right ventricle, and free-
running (false tendons of) Purkinje fibres were isolated from both ventricles of hearts 
removed through a right lateral thoracotomy from anesthetized (thiopental 30 mg/kg i.v.) 
mongrel dogs of either sex weighing 10 - 15 kg. The preparations were placed in a tissue bath 
and allowed to equilibrate for at least 2 h while superfused (flow rate 4-5 ml/min) with 
Locke’s solution containing (in mM): NaCl 120, KCl 4, CaCl2 2, MgCl2 1, NaHCO3 22, and 
glucose 11. The pH of this solution was 7.40 to 7.45 when gassed with 95% O2 and 5% CO2 
at 37°C. During the equilibration period, the ventricular muscle tissues were stimulated at a 
basic cycle length of 1000 ms, Purkinje fibres were stimulated at a basic cycle length of 500 
ms. Electrical pulses of 2 ms in duration and twice diastolic threshold in intensity (S1) were 
delivered to the preparations through bipolar platinum electrodes. Transmembrane potentials 
were recorded with the use of glass capillary microelectrodes filled with 3 M KCl (tip 
resistance: 5 to 15 MΩ). The microelectrodes were coupled through an Ag-AgCl junction to 
the input of a high-impedance, capacitance-neutralizing amplifier (Experimetria 2004). 
Intracellular recordings were displayed on a storage oscilloscope (Hitachi V-555) and led to a 
computer system (APES) designed for on-line determination of the following parameters: 
resting membrane potential, action potettial amplitude, action potential duration at 50% and 
90% repolarization and the maximum rate of rise of the action potential upstroke (Vmax). The 
following types of stimulation were applied in the course of the experiments: stimulation with 
a constant cycle length of 1000 ms (ventricular muscles); stimulation with a constant cycle 
length of 500 ms (Purkinje fibres); stimulation with different constant cycle lengths ranging 
from 300 to 5000 ms (or to 2000 ms in the case of Purkinje fibres to prevent spontaneous 
diastolic depolarizations at cycle lengths longer than 2000 ms). To determine the recovery 
kinetics of Vmax, extra test action potentials were elicited by using single test pulses (S2) in a 
preparation driven at a basic cycle length of 400 ms. The S1-S2 coupling interval was 
increased progressively from the end of the refractory period. The effective refractory period 
was defined as the longest S1-S2 interval at which S2 failed to elicit a propagated response. The 
diastolic intervals preceding the test action potential were measured from the point 
corresponding to 90% of repolarization of the preceding basic beat to the upstroke of the test 
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action potential and were increased progressively. To determine the onset kinetics the 
preparations were continuously stimulated at cycle length of 1000 ms, the stimulation was 
interrupted for 1 min, and then a train of 40-beat stimuli was applied with a cycle length of 
400 ms. Control recordings were obtained after equilibrium period. The effects of ivabradine 
were determined at the given concentrations, with recordings started 25 minutes after the 
addition of each concentration of the drug in a cumulative manner. For all experiments 
ivabradine (Sequoia Research Products Ltd, Pangbourne, United Kingdom) was dissolved in 
distilled water at stock solution concentration of 1 or 10 mM. Compounds EC18 and 
MEL57A were kindly provided in the frame of collaboration with Prof. Elisabetta Cerbai’s 
research group, University of Florence; compounds EC18 and MEL57A were dissolved in 
DMSO. 
 
2.2.2 Human tissue 
 
Non-diseased human hearts that were technically unusable for transplantation (based on 
logistical, not patient-related, considerations) were obtained from organ donors. Before 
cardiac explantation, organ donor patients did not receive medication except dobutamine, 
furosemide and plasma expanders. The investigations conform to the principles outlined in the 
Declaration of Helsinki of the World Medical Association. All experimental protocols were 
approved by the Scientific and Research Ethical Committee of the Medical Scientific Board at 
the Hungarian Ministry of Health (ETT-TUKEB), under ethical approval No 4991-0/2010-
1018EKU (339/PI/010). Human cardiac tissue was stored in cardioplegic solution at 4°C for 
4–8 hour. Papillary muscles were obtained from the right ventricle. Preparations were initially 
stimulated at a basic cycle length of 1000 ms and allowed at least 1 hour to equilibrate while 
they were continuously superfused with Locke’s solution. Temperature of the superfusate was 
kept constant at 37°C. 
 
2.3 Statistical analysis 
 
Results were analyzed by using Student’s t-test for paired and unpaired data. Differences were 
considered significant when p < 0.05. Data are expressed as mean ± S.E.M. (standard error of 
the mean). 
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3.   RESULTS 
 
3.1 Effects of ivabradine on ionic currents 
The effects of the drug on rapid delayed rectifier (IKr), the transient outward (Ito) and the 
inward rectifier (IK1) potassium currents were measured in rabbit and dog ventricular 
myocytes. 10 µM ivabradine did not influence IK1 (control: 365±73 pA, drug: 361±83 pA, at -
60 mV test potential, n=5) in rabbit ventricular myocytes (Fig. 1A). The drug did not affect Ito 
in rabbit (control: 496±101 pA, drug: 479±76 pA, at 50 mV test potential, Fig. 1B, n=5), and 
in dog ventricular myocytes (control: 2592±577 pA, drug: 2573±516 pA, at 50 mV test 
potential, Fig. 1C, n=4).  
 
 
Fig. 1. Effect of ivabradine on IK1 in rabbit ventricular myocyte (A, n=5); effect of ivabradine 
on Ito in rabbit ventricular myocyte (B, n=5); effect of ivabradine on Ito in dog ventricular 
myocyte (C, n=4). 
 
In rabbit ventricular myocytes the amplitude of IKr was decreased concentration-dependently 
by ivabradine with an estimated IC50 value of 3.5 µM (Fig. 2A, 2B). 
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Fig. 2. Effect of ivabradine on IKr in rabbit ventricular myocyte (A, n=5); concentration-
dependent effect of ivabradine on IKr in rabbit ventricular myocyte (B, n=3-5).  
 
 
3.2 Effects of ivabradine on  transmembrane action potentials 
 
 
In dog Purkinje strands, stimulation (2 Hz) was terminated to allow development of 
spontaneous activity. The developed spontaneous frequency in the control preparations was 
0.471 ± 0.06 Hz. Ivabradine concentration-dependently decreased the amplitude of 
spontaneous diastolic depolarization (Fig. 3B, n=6) and slowed spontaneous rate of firing 
(Fig. 3A, n=5) of the Purkinje fibres. Spontaneous activity was completely abolished by 10 
µM ivabradine in all preparations.  
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Fig. 3. Effect of ivabradine on the spontaneous action potential (AP) firing (A, representative 
figures) and the amplitude of spontaneous diastolic depolarization (B, results are mean ± 
S.E.M., *=P<0.05 vs control, n=6, cumulative drug application) in dog Purkinje fibre. 
 
In isolated dog Purkinje fibres ivabradine concentration– and rate-dependently decreased the 
maximum rate of rise of the action potential upstroke (Vmax , n=11), and action potential 
amplitude while action potential duration measured at 50% of repolarization was shortened in 
a concentration-dependent manner (n=8) at pacing with a constant cycle length of 500 ms 
(Table 1, and Fig. 4). 
The depression of Vmax evoked by 0.1 and 1 and 10 µM ivabradine was strongly dependent 
upon stimulation frequency (“use-dependent”); i.e., as pacing cycle length was decreased, the 
depression of Vmax was increased.  
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Fig. 4. Rate- and dose-dependent effect of ivabradine on the maximum rate of depolarization 
(Vmax) (A, results are mean ± S.E.M., *=P<0.05, **=P<0.01 vs control, n=11, cumulative 
drug application) and concentration-dependent effect of the drug on the AP waveform/plateau 
(B, representative figure ) in dog Purkinje fibre (recordings originate from the same 
preparation). 
 
Table 1: The electrophysiological effects of ivabradine in dog Purkinje fibers at basic cycle 
length of 500 ms. 
 
Parameters MDP (mV) APA (mV) APD50 (ms) APD90 (ms) Vmax  (Vs-1) 
Control -88.3 ±1.0 129.4 ± 1.9 170.0 ± 9.8 245.7 ± 7.5 640.7 ± 38.4 
Ivabraine 
0.1 µM -88.0 ± 0.9 127.5 ± 1.9 168.8 ± 7.2 248.6 ± 6.2 591.7 ± 36.4 
Ivabraine 
1 µM -88.5 ± 1.5 126.5 ± 2.8 165.8 ± 8.8 252.0 ± 6.8 556.8 ± 42.8 
Ivabraine 
10 µM -88.1 ± 1.5 122.6 ± 2.4
a 137.7 ± 10.3a 242.8 ± 7.7 471.8 ± 38.1a 
 
MDP, maximum diastolic potential; APA, action potential amplitude; APD50 and APD90, 
action potential durations at 50% and 90% of repolarization; Vmax, maximal rate of 
depolarization. Results are mean ± S.E.M. a p < 0.05. n=8. 
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Fig. 5. Onset of frequency-dependent depression of Vmax induced by 10 µM ivabradine in dog 
ventricular muscle at stimulation cycle length of 400 ms. Mean values are given from 7 
experiments (A); effect of 10 µM ivabradine on recovery of Vmax in dog ventricular muscle at 
stimulation cycle length of 400 ms. Mean values are given from 8 experiments (B). 
 
In dog ventricular muscles (n=7) stimulated at the cycle length of 400 ms the onset kinetics of 
Vmax block induced by 10 µM ivabradine was fitted to a single exponential, resulting in the 
onset rate kinetic constant of  13.9 ± 3.2 beat -1 (Fig. 5A). In dog ventricular muscles (n=8) at 
the basic cycle length of 400 ms, the recovery of Vmax during control was best fit to a single 
exponential relation (Fig. 5B). The time constant for recovery of Vmax during control was fast 
(τfast = 46.2 ± 4.3 ms) and before final repolarization of the basic action potential, it was 
almost complete. In the presence of 10 µM ivabradine the recovery kinetics of Vmax was best 
fit with a two exponential relation. In addition to a fast component (τfast = 41.2 ± 8.2 ms) 
which reflects recovery of the drug-free sodium channels [93], a slow component (τslow = 8.76 
± 1.34 s) of recovery of  Vmax was revealed following exposure to ivabradine. This second 
slow component for recovery of Vmax may reflect effects on drug-affected sodium channels 
[93] (Fig. 3B).  
 
In dog ventricular muscle (n=8) at a stimulation cycle length of 1000 ms the drug moderately 
and in a concentration dependent manner prolonged the action potential duration (Fig. 6, 
Table 2), while after attenuation of the repolarization reserve by inhibition of the inward 
rectifier potassium current (n=5) by adding 30 µM BaCl2 it further lengthened the ventricular 
repolarization at concentrations of 1 and 10 µM. (Fig. 6, Table 3).  
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Fig. 6. Effect of ivabradine on action potential waveform of dog ventricular muscle with 
normal (on the left, top and bottom figures, showing the same representative experiment) and 
attenuated repolarization reserve (on the right, top and bottom, illustrating 2 different 
representative experiments) at stimulation cycle length of 1000 ms (action potential waveform 
recordings originate from the same preparation, per experiment). 
 
Table 2. The electrophysiological effects of ivabradine in dog ventricular muscle preparations 
at basic cycle length of 1000 ms.
 
 
Parameters MDP (mV) APA (mV) APD50 (ms) APD90 (ms) Vmax  (Vs-1) 
Control -86.3 ±1.2 106.5 ± 1.5 190.1 ± 4.1 223.9 ± 5.9 201.1 ± 17.2 
Ivabraine 
0.1 µM -86.3 ± 1.0 106.7 ± 1.8 195.0 ± 4.7
b 229.0 ± 5.7a 205.7 ± 21.6 
Ivabraine 
1 µM -85.4 ± 0.8 107.2 ± 2.1 199.0 ± 5.3
b 233.5 ± 6.0a 212.1 ± 20.2 
Ivabraine 
10 µM -87.6 ± 1.1 106.1 ± 2.4
 205.0 ± 5.0a 243.8 ± 6.5a 181.8 ± 20.3 
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MDP, maximum diastolic potential; APA, action potential amplitude; APD50 and APD90, 
action potential durations at 50% and 90% of repolarization; Vmax, maximal rate of 
depolarization. Results are mean ± S.E.M. a p < 0.01; bp < 0.05. n=8. 
 
Table 3. The electrophysiological effects of ivabradine in dog papillary muscles after 
impairing the repolarization reserve.  
 
Parameters MDP (mV) APA (mV) APD50 (ms) APD90 (ms) Vmax  (Vs-1) 
Control -83.1 ± 1.5 107.8 ± 2.1 159.2 ± 10.7 200.7 ± 10.9 223.0 ± 26.9 
BaCl2 
30 µM -83.8 ± 3.0 105.9 ± 1.9 171.0 ± 19.0 239.1 ± 18.5
b 232.0 ± 26.4 
Ivabraine 
1 µM -84.6 ± 2.7 109.9 ± 2.2
b 197.1 ± 17.0b 263.3 ± 17.6b 249.8 ± 34.2 
Ivabraine 
10 µM -85.8 ± 2.2 108.9 ± 1.5
a 230.2 ± 21.7a 306.8 ± 22.0a 230.4 ± 33.0 
 
MDP, maximum diastolic potential; APA, action potential amplitude; APD50 and APD90, 
action potential durations at 50% and 90% of repolarization; Vmax, maximal rate of 
depolarization. Results are mean ± S.E.M. a p < 0.01; bp < 0.05. n=5. 
 
In human ventricular muscle preparations (n=4) at a stimulation cycle length of 1000 ms 1 
µM ivabradine did not change ventricular repolarization and a small, but significant 
prolongation of the action potential repolarization was observed only in the presence of high 
(10 µM) concentration of ivabradine ( Table 4). 
 
Table 4. The electrophysiological effects of ivabradine in nondiseased human ventricular 
muscle preparations at basic cycle length of 1000 ms. 
 
Parameters MDP (mV) APA (mV) APD50 (ms) APD90 (ms) Vmax  (Vs-1) 
Control -86.1 ± 0.6 108.2 ± 5.0 198.1 ± 17.0 255.9 ± 21.2 299.8 ± 24.5 
Ivabradine 
1 µM -86.1 ± 0.1 107.3 ± 5.8 202.0 ± 18.9 260.6 ± 21.6 277.8 ± 48.7 
Ivabradine 
10 µM -86.5 ± 1.3 104.8 ± 5.8 203.2 ± 19.0 271.0 ± 21.8
a 242.9 ± 48.0 
 
MDP, maximum diastolic potential; APA, action potential amplitude; APD50 and APD90, 
action potential durations at 50% and 90% of repolarization; Vmax, maximal rate of 
depolarization. Results are mean ± S.E.M. a p < 0.01. n=4. 
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3.3 Effects of compounds EC18 and MEL57A on transmembrane action potentials 
 
We investigated the effects of compounds EC18 and Mel 57A on the action potential 
parameters of dog papillary muscle preparations and Purkinje fibers.  
EC18 has similar action on the spontaneous diastolic depolarization (Fig. 7.) to ivabradine 
(i.e. dose-dependently reduced the amplitude of diastolic depolarization phase) and at 10 µM, 
decreased the AP plateau in dog Purkinje fibre (Fig. 8).  
 
Fig. 7. Effect of EC18 on the amplitude of spontaneous (left, representative experiment) 
diastolic depolarization (histograms represent mean ± S.E.M., *=p<0.05 vs control, n=5, 
cumulative drug application) in dog Purkinje fibre. 
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Fig. 8. Concentration-dependent effect of compounds EC18 and MEL57A on the AP 
waveform/plateau (representative figures) in dog Purkinje fibre (in each representative 
treatment group recordings originate from the same preparation). 
 
In dog ventricular muscle preparations, EC 18 did not influence the repolarization (Table 5).  
 
Table 5: The electrophysiological effects of EC18 in dog papillary muscle preparations at 
basic cycle length of 1000 ms. 
 
Papillary muscle MDP (mV) APA (mV) APD50 (ms) APD90 (ms) Vmax  (Vs-1) 
Control -85.2 ± 1.4 105.1 ± 2.5 177.4 ± 15.6 213.9 ± 15.8 238.7 ± 28.6 
EC18 
1 µM -85.3 ± 1.7 104 ± 1.4 169.1 ± 13.3 206.1 ± 13.0 232.9 ± 33.6 
          EC18 
10 µM -84.5 ± 1.4 102.8 ± 1.3 178.8 ± 14.1 215.4 ± 12.4
 140.6 ± 20.2 a 
 
MDP, maximum diastolic potential; APA, action potential amplitude; APD50 and APD90, 
action potential durations at 50% and 90% of repolarization; Vmax, maximal rate of 
depolarization. Results are mean ± S.E.M. b p < 0.05 ; a p < 0.01 ; n=5. 
 
MEL57A did not affect spontaneous diastolic depolarization in dog Purkinje fibres (Fig. 9.), 
but at 1 and 10 µM dose-dependently decreased the AP plateau in dog Purkinje fibre (Fig. 8.) 
.  
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Fig. 9. Effect of MEL57A on the amplitude of spontaneous (left, representative experiment) 
diastolic depolarization (histograms represent mean ± S.E.M., *=p<0.05 vs control, n=5, 
cumulative drug application) in dog Purkinje fibre. 
 
In dog ventricular muscle preparations, MEL57A did not influence the repolarization (Table 
6). 
 
Table 6: The electrophysiological effects of MEL57A in dog papillary muscle preparations at 
basic cycle length of 1000 ms. 
 
Papillary muscle MDP (mV) APA (mV) APD50 (ms) APD90 (ms) Vmax  (Vs-1) 
   Control -83.3 ± 1.4 107.2 ± 1.8 169.3 ± 8.3 200.8 ± 8.8 234.2 ± 16.3 
       MEL57A 
1 µM -83.4 ± 1.5 107.4 ± 2.0 169.1 ± 6.4 208.1 ± 6.9 228.3 ± 13.5 
          MEL57A 
10 µM -83.7 ± 1.3 108.7 ± 2.5 175.7 ± 4.8 208.7 ± 4.9
 209.0 ± 11.2  
 
MDP, maximum diastolic potential; APA, action potential amplitude; APD50 and APD90, 
action potential durations at 50% and 90% of repolarization; Vmax, maximal rate of 
depolarization. Results are mean ± S.E.M. b p < 0.05 ; a p < 0.01 ; n=5. 
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4.   DISCUSSION 
 
 
Some of the results is confirmation of previous findings in small animals at high 
concentration i.e. ivabradine (S16257) at 50 µM induces frequency-dependent Vmax block and 
at 3 and 10 µM prolongs repolarization in guinea-pig papillary muscles [90, 53]. The main 
new finding of the present study is that ivabradine in large animal (dog) and human cardiac 
preparations, in addition to decreasing heart rate, inhibits Vmax , IKr , and at a concentration 
higher than 1 µM moderately prolongs APD i.e. exerts combined Class I, Class III and Class 
V antiarrhythmic actions. 
 
4.1 Possible ionic mechanisms 
 
We have examined the specific ionic mechanisms by which ivabradine affects action potential 
configuration. Repolarization lengthening could be related to the IKr block found in rabbit 
isolated ventricular myocytes. Dose- and frequency dependent Vmax block  in dog Purkinje-
fibres could be attributed to the  inhibitory effect of ivabradine on the fast Na+ current. Vmax 
measurements are indicative for INa function, but can not be used for quantitative estimation of 
sodium channel availability, which could be underestimated by such measurements [93], since 
Vmax can be regarded as a nonlinear indicator of the fast inward sodium current [94]. Block of 
sodium current has been demonstrated to be more pronounced when the resting membrane 
potential is partly depolarized [95] e.g. in ischaemic tissues. The effects of ivabradine on 
recovery of Vmax observed in isolated ventricular muscle indicate that ivabradine resembles 
kinetically slow antiarrhythmic agents. According to reported data [96] at 10 µM 
concentration ivabradine does not exhibit a 100% blockade of the If current, therefore 
additional factors such as inhibitory effect on sodium channels can not be excluded as 
possible contributor. A slowly activating sodium current, INa3, has been described by patch-
clamp analysis in the late diastolic depolarization of dog single Purkinje cells. This current is 
sensitive to lidocaine and tetrodotoxin, and contributes to attainment of the threshold for the 
upstroke in the oscillary range of late diastolic depolarization [97]. Another possible 
explanation might be the functional subunit interspecies and tissue specific difference of 
hyperpolarization-activated cyclic nucleotide gated (HCN) channels [98]. 
Inhibition of IKr by ivabradine at higher concentrations might also influence the spontaneous 
diastolic depolarization in Purkinje fibres owing to the „K+ current decay hypothesis” [99]. 
Effect on the plateau slope might be related to the inhibitory effect of ivabradine on the 
persistent, ’window’ Na+ current. Block of this Na+ current might also have an additional 
therapeutic value [100] and would also limit action potential prolongation at slow rate due to 
the IKr inhibition of the drug at higher concentration. In this context it has to be mentioned 
that similar relatively high (2.8 µM) IC50 of ivabradine was reported on If in rabbit sinus node 
cells [96]. Therefore, the possible decrease of INa by the drug may contribute to the inhibition 
of the pacemaker function. 
 
4.2 Possible clinical implications 
 
As the present study shows, ivabradine, in addition to blocking the pacemaker current, at 
micromolar concentration ranges also inhibits the rapid component of the delayed rectifier 
potassium current, and presumably, the sodium channels. Though therapeutic plasma 
concentrations of ivabradine are about 0.04-0.07 µM, the drug has been tested at higher (0.17 
µM) concentration in healthy volunteers [101], therefore the (0.1-1-10 µM) concentrations 
applied in our experiments may be relevant, since the tissue concentration can be expected to 
be higher than that of the plasma, in accordance with the high volume of distribution (close to 
100 L) value of the drug. In this context, the relatively low therapeutic plasma concentration 
might be the result of possibly meaningful tissue appearance of ivabradine, therefore, we can 
not underestimate the probable INa and the proven IKr blocking ability of ivabradine at higher 
concentrations. Mostly, because CHF (congestive heart failure) -induced impairments (e.g. 
deterioration in Vmax) in dog Purkinje tissue conduction have been lately reported [102]. It has 
to be emphasized that the drug so far has proved to be safe and free from any proarrhythmic 
events in clinical trials [103,104]. However, considering the bradycardic action of the drug, 
possible very rare proarrhythmic episodes can not be completely ruled out in certain, special 
cases during application of ivabradine, especially in some pathological conditions, e.g. in case 
of drug accumulation or intoxication, or in case of attenuated repolarization reserve like in 
heart failure, diabetes or in LQT. On the other hand, the mild sodium channel blocking ability 
on Purkinje fibres might be considered as an antiarrhythmic property and might suppress the 
initiation of an extrasystole, limit any repolarization lengthening and most importantly, it 
could decrease dispersion of repolarization. The frequency-dependent Vmax block might 
diminish conduction of early extrasystoles or bursts with fast rates which potentially elicit 
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cardiac arrhythmias in the presence of an ischaemic cardiac substrate. Therefore, the most 
conspicious finding was that this bradycardic drug might possess subsidiary antiarrhythmic 
actions, which can be utilized in the therapy.  
 
4.3 Electrophysiological effects of compounds EC18 and MEL57A 
 
We also investigated compounds EC18 and MEL57A on dog papillary muscles where they 
did not influence repolarization and on cardiac Purkinje fibers, a cardiac subsidiary 
pacemaker exhibiting spontaneous diastolic depolarization, where isoforms HCN4 and HCN2 
have been suggested to be the prevalent f-channel isoforms at variance with isoform HCN1 
which is no – or poorly – expressed in mammalian heart [105], including humans [106]. EC18 
strongly decreased the amplitude of Purkinje fibers diastolic depolarization phase. On the 
contrary, MEL57A did not change the diastolic depolarization phase. This latter observation 
suggests that HCN1 selective inhibitors may be devoid of – or with less pronounced - cardiac 
adverse effects while HCN4 blockers may be active also at ventricular level. Given HCN4 
overexpression in cardiomyopathies such as in case of heart failure [84, 86, 107], such a 
property might be advantageous possessing potential antiarrhythmic effects. Effect of EC18 
and MEL57A on Purkinje fibre AP plateau might indicate subsidiary sodium channel or L-
type calcium channel inhibition. 
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5. CONCLUSIONS 
 
Based on the cellular cardiac electrophysiological properties of ivabradine it can be concluded 
that the drug, in addition to its well established bradycardic effect, also shows Class I and III 
antiarrhythmic properties which can be advantageous to treat patients with ischaemic heart 
disease, heart failure [108] liable to disturbances of cardiac rhythm. 
 
Concerning –in general- the bradycardic agents the HCN4 isoform selectivity is desirable 
according to its prominent role in cardiac pacemaking [79, 80]. Reaching the lack of visual 
side effects (attributable to the retinal Ih block) would be advantageous in future development. 
As to the arrhythmogenic potency of HCN4 and HCN2 upregulation in the working 
myocardium of the failing heart, simultaneous block of them seems to be a feasible 
opportunity. As it was seen in the history of development of beta blocker generations, 
valuable subsidiary effects (alfa-blocker, antioxidant, very high beta1 selectivity) were 
discovered at some relatively new representatives of them. In case of If blockers, similar 
phenomen might happen, adding extra beneficial property to future bradycardic compounds. 
HCN1 isoform selective Ih inhibitors (MEL57A) might be appropriate for the treatment of 
neuropathic pain associated with nerve injury [7]. The HCN1 isoform also play an important 
role in the effect of general anaesthetic agents. Regarding the potential adverse effects, and 
considering that HCN channels are also expressed in liver, testis and pancreas it can be stated 
that synthetizing a well tolerable, safe agent is very important, and therefore the isoform 
selective approach might be the basis of future developments.  
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